Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial. - Loper M; Qadar A; Vesely SK; Gunter T; Ayanambakkam A; Wen Y; Cookson M; Stratton K (BMJ open, 2026)